Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031666 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants
A Phase 1 study, sponsored by Aragon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT02031666 is a Phase 1 study that has completed, run by Aragon Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT02031666, a Phase 1 study, has completed, sponsored by Aragon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication) and relative bioavailability (the extent to which a medication or other substance becomes available to the body) of JNJ-56021927 when administered as 7 test tablet formulations of JNJ-56021927 compared with the softgel capsule formulation of JNJ-56021927 in healthy male participants under fasted conditions at a single dose of 240 mg.
Interventions
- DRUG JNJ-56021927 capsule
- DRUG JNJ-56021927 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02031666
The ClinicalTrials.gov registry entry for NCT02031666 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-56021927 capsule is the first listed.
NCT02031666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02031666 about?
NCT02031666 is a clinical study titled "A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants". The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication) and relative bioavailability (the extent to which a medication or other substance becomes available to the body) of JNJ-56021927 when administered as 7 test tablet formulations of JNJ-56021927 compar...
What is the current status of trial NCT02031666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2013-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02031666?
The interventions under investigation include: JNJ-56021927 capsule (DRUG), JNJ-56021927 tablet (DRUG).
Who is sponsoring clinical trial NCT02031666?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.